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AtherosclerosisIt is well established that atherosclerotic cardiovascular disease (ACD) is a leading cause of death in the West.
There are several predisposing factors for ACD, which can be divided into two groups: ﬁrstly modiﬁable risk
factors, including hypertension, dyslipidaemia, type 2 diabetes mellitus, obesity, smoking and a sedentary
lifestyle and secondly the unmodiﬁable risk factors such as age, gender and heredity. Since single biomarkers
are unable to provide sufﬁcient information about the biochemical pathways responsible for the disease, there
is a need for a holistic approach technology, e.g., metabolomics, that provide sufﬁciently detailed information
about the metabolic status and assay results will be able to guide food, drug and lifestyle optimisation. Rather
than investigating a single pathway, metabolomics deal with the integrated identiﬁcation of biological and
pathologicalmolecular pathways.Mass spectrometry (MS) andnuclearmagnetic resonance (NMR) spectroscopy
are the two most commonly used techniques for metabolite proﬁling. This detailed review concluded that
metabolomics investigations seem to have great potential in identifying small groups of disturbed metabolites,
which if put together should draw various metabolic routs that lead to the common track pathophysiology.
The current evidence in using metabolomics in atherosclerotic cardiovascular disease is also limited, and more
well-designed studies remain to be established, which might signiﬁcantly improve the comprehension of
atherosclerosis pathophysiology and consequently management.
© 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND 4.0
license (http://creativecommons.org/licenses/by/4.0/).1. Introduction
It is well established that atherosclerotic cardiovascular disease (ACD)
is a leading cause of death in theWest [1]. It is a chronic inﬂammatory dis-
order [2] that begins in early childhoodwith fatty streak formation in the
coronary arteries [3] and remains silent until late adulthood, when lipids
start to accumulate in the intima forming atherosclerotic plaques [4].
There are several predisposing factors for ACD, which can be divided
into two groups: ﬁrst, modiﬁable risk factors, including hypertension,
dyslipidaemia, type 2 diabetesmellitus, obesity, smoking and a sedentary
lifestyle and, second, the unmodiﬁable risk factors such as age, gender and
heredity [5]. Ageing is the predominant risk factor for ACD, and it renders
many of the modiﬁable risk factors more prevalent and more severe [6].
Thus, the aetiology of atheroma formation is multifactorial with a syner-
gistic effect of many risk factors. At present, cardiologists remain using
conventional risk factors, derived from the Framingham studies [7].
Although helpful, those risk factors do not detect all instances of CAD,
and indeed a signiﬁcant percentage of patientswithmyocardial infarction
has no conventional risk factors [8]. Othermarkers such as coronary calci-
ﬁcation have been found to improve risk stratiﬁcation but still fall a longHenein).
land Ltd. This is an open access articway short of 100% prediction [8]. Conventional coronary angiography
is invasive, time consuming and expensive and subjects the patient to
radiation, while computed tomography coronary angiography (CTCA)
also suffers from many of the same limitations.
On the other hand, single disease biomarkers are always desired to
identify risk factors or people affected by a disease to evaluate progress
or to monitor an intervention in treating the disease. This principle has
been shown useful for, e.g., bacterial infections, where a speciﬁc mole-
cule or groups of molecules are characteristic of the disease state and
largely distinctive within the matrix being sampled. The commonly
investigated biomarker in ACD is cholesterol. However, serum choles-
terol levels may fail to identify the exact pathway to their abnormal
levels since sources of increased cholesterol levels are not only food
but also endogenous biosynthesis or slow conversion to bile acids [9].
Since single biomarkers are unable to provide sufﬁcient information
about the biochemical pathways responsible for the disease, there is a
need for a holistic approach technology, e.g.,metabolomics, that provide
sufﬁciently detailed information about the metabolic status and assay
results will be able to guide food, drug and lifestyle optimisation [9].
The metabolome refers to the complete set of small molecule (low
molecular weight (b1500 Da)) metabolites in a cell, tissue, organ or
organism [10], while metabolomics is the comprehensive analysis and
quantiﬁcation of these small molecules based on bioﬂuids and tissuele under the CC BY-NC-ND 4.0 license (http://creativecommons.org/licenses/by/4.0/).
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mics deal with the integrated identiﬁcation of biological and pathological
molecular pathways [13].
Roger William together with colleagues were the ﬁrst pioneers who
introduced the concept, in late 1940s, that individualsmight have ameta-
bolomics proﬁle, which could be reﬂected in the ‘structure’ of the biolog-
ical ﬂuids. By utilising paper chromatogram, William examined taste
threshold and the excretion proﬁles from alcoholics and schizophrenics.
He linked each of these disorder with a speciﬁc metabolic proﬁle [14].
In 1960s and 1970s, gas chromatography and liquid chromatography
further advanced the technique, which made them more available [15].
The term metabolic proﬁle was ﬁrst introduced by Hornings et al. in
early 1970s [16]. They suggested that metabolic proﬁles may be valuable
for characterising both normal and disease state. The ‘-omics’ approach
includes genomics, transcriptomics, proteomics and the rapidly emerging
metabolomics [17].
Mass spectrometry (MS) and nuclear magnetic resonance (NMR)
spectroscopy are the twomost commonly used techniques for metabo-
lite proﬁling [18]. Each of these techniques has important strengths and
weaknesses. For example, MS is innately more sensitive than NMR but
requires a prior separation ofmetabolites using chromatography (liquid
or gas chromatography) or capillary electrophoresis (CE) [19]. Further,
the ionisation or ion suppression effect could impair the analytic quan-
tiﬁcation. The MS can, with standard techniques, detect smaller metab-
olites than NMR (picomolars for MS and micromolars for NMR), and
those metabolites detected with NMR need to contain a hydrogen
atom. By using NMR sample, recovery is non-destructive, and the
sample is analysed in only one measurement while for MS only a
small amount of sample is used that eventually will be destructed [20].
Both techniques can be used to characterise metabolic data in a
targeted or non-targeted aspect. For the targeted approach, the investiga-
tor focuses on a limited set of metabolites of known identity. Untargeted
approach deals with the investigation of as many peaks as possible, with
unknownunderlying identities of the species. Therefore, untargeted anal-
yses are considered more sensitive and more likely to discover new bio-
markers, while target analyses are used in biomarker validation [21].
Because of data complexity, NMR can assign deﬁnitive metabolite identi-
ties to only a subset of peaks arising from the sample. Although MS can
generate sometimes thousands of peak metabolites from the bioﬂuids,
chromatographic extraction time and mass to change ratio are often in-
sufﬁcient to conﬁdently assign peak intensities [21]. The organisation of
the humanmetabolome database (HMDB) is a comprehensive online da-
tabase that gathers small molecule metabolites found within the human
body. The HMDB second version, produced in 2009, was able to identify
6500 metabolites [22] and the latest version available from 2013 has sig-
niﬁcantly expanded to identify more than 40.000 metabolites [23].
During the last decade, there has been growing interest in the appli-
cation of metabolomics for early disease prevention and to potentiate
drug development and therapy monitoring [8,9]. In the setting of coro-
nary atherosclerosis, metabolomics has been shown to identify a num-
ber of disordered biomarkers, some of which may be susceptible to
modiﬁcation. The development of a set of metabolites which could aid
prediction of ACD would certainly be welcomed. Furthermore, it is pos-
sible that urine or salivary samples may be used for metabolic analysis,
which even avoids the need for phlebotomy. In this review, we will
discuss the latest metabolomic approaches within the ﬁeld of ACD and
its related risk factors.
2. Atherosclerosis
2.1. Animal studies
Lyso-phosphatidylcholine (LPC) is a class of phospholipids that are
intermediates in the metabolism of lipids. LPC is generated by an
enzyme found on oxidised LDL called lipoprotein-associated phospholi-
pase A2 from phosphotidylcholine [24]. Increased levels of this enzymehave been associated with higher risk of developing ACD [25]. LPC is
involved with early pro-inﬂammatory events occurring in the initial
state of a plaque formation by increasing adhesion of monocytes on
endothelial cells, as well as activating inﬂammatory genes (NF-KB)
during fatty streak development. This leads to the activation of apo-
ptosis, necrosis and formation of cholesterol crystals which causes
plaque vulnerability [26]. Clish et al. [27] found that using highly
performing liquid chromatography–mass spectrometry (HPLC-MS),
lyso-PC was elevated in the liver of the apolipoprotein E3 (Apo E3)
Leiden transgenic mouse (susceptible to development of ACD) in
contrast to controls.
In another study by Kleemann et al. [28], ApoE Leidenmicewere fed
a low vs. high cholesterol diet. The amount of dietary cholesterol posi-
tively correlated with development of atherosclerosis. With increasing
dietary cholesterol intake, the liver switched from a mainly resilient to
a predominantly inﬂammatory state, which is associated with early
lesion formation. The high cholesterol evoked changes involving specif-
ic transcriptional master regulators, some of which are established,
others newly identiﬁed, several of these regulators control both lipid
metabolism and inﬂammation and thereby link the two processes. The
liver and plasma were analysed with HPLC/MC identiﬁed disturbance
in di-and triglycerides, phosphatidylcholines, lysophosphatidylcholines
and cholesterol esters.
The effect of different diets on atheroma formation has been also
studied.Martin et al. investigated the effect of several diets fed to hyper-
lipidaemic hamsters and observed that aortic cholesteryl ester, assessed
by NMR spectroscopy, was an early accumulator in atherogenic plaques.
The lowest atherogenicity was obtained with the plant-oil cheese diet,
followed by the dairy fat cheese diet, while the greatest atherogenicity
was observedwith the butter diet. Aortic cholesteryl ester was positive-
ly correlated with very low density lipoprotein (VLDL), cholesterol and
N-acetylglycoproteins and negatively correlated with trimethylamine-
N-oxide (TMAO) and albumin lysyl [29].
Likewise, Jove et al. observed that a high-fat diet caused an increase
in ceramide and docosahexaenoic acid (DHA) in plasma and a tissue
sample from the aorta. Free cholesterol in the aorta was positively
correlatedwith taurocholic acid, suggesting that it could be a biomarker
for early atherogenesis [30]. Furthermore, a high-fat cholesterol choate
(HFCC) diet has been shown to alter plasma and urinary metabolism in
LDL-receptor-deﬁcient mice using H-NMR spectroscopy. The HFCC diet
caused a signiﬁcant perturbation in choline metabolism, notably the
choline oxidation pathway a signiﬁcant reduction in the urinary excretion
of taurine, betaine and dimethylglycine [31].
In addition to these studies, recent ones showed that not only diet
and liver have a role in the development of atherosclerosis but also
gut ﬂoras have demonstrated great importance. It has been suggested
that microbiome, i.e., the collective genomes of the microorganisms
that reside in the gut, can increase cardiovascular risk either via metabo-
lism of L-carnitine [32] or phosphatidylcholine (Wang at al 2011). Mice
were given either a control diet or a diet rich in choline. The gutmicroﬂora
was suppressed in half of themice given broad-spectrum antibiotics [33].
Upon analyzing the plasma, TMAO was suppressed to a non-detectable
level. The development of the aortic root lesion was increased 3-fold in
mice not treatedwith antibiotics, and hencewith preserved gutmicroﬂo-
ra, and in those fed a choline-enhanced diet. Thus, Wang et al. supposed
that dietary supplements of choline, TMAO and betaine (which are all
metabolites of phosphatidylcholine) could enhance the development of
atherosclerosis. Furthermore, it was proposed that these metabolites are
involved in the upregulation of scavenger receptors on macrophages
hence the formation of foamy cells.
In another study, Stöhr et al. [34] also linked atherosclerosis to the
metabolism of carnitine. By using a targeted metabolomic approach,
the group studied the plasma of genetically modiﬁed mice susceptible
to atherosclerosis. Interestingly, they observed a decrease in the blood
concentration of free carnitine, acetylcarnitine and glutarylcarnitine/3-
hydroxy-hexanoylcarnitine.
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Brindle et al. [35] were the ﬁrst to investigate the use of metabolo-
mics for the diagnosis of ACD. They could not only conﬁrm the presence
of ACD but also distinguish its severity by usingH-NMR spectroscopy on
human sera. A supervised partial least squares discriminant analysis to
orthogonal signal-corrected data sets allowed N90% of subjects with
stenosis of all three major coronary vessels to be distinguished from
subjectswith angiographically normal coronary arteries, with a speciﬁc-
ity of N90%. In general, the regression coefﬁcients, or loadings, most
inﬂuential for the triple vessel disease (TVD) samples lie around δ0.86
(due mainly to CH3 groups from fatty acid side chains in lipids, in partic-
ular, LDL and VLDL) and δ 1.26, δ1.3 and δ1.34 (due mainly to (CH2)n
groups from fatty acid side chains in lipids, in particular VLDL and LDL).
The loadings most inﬂuential for the normal coronary artery (NCA) sam-
ples lie around δ1.22 (due mainly to (CH2)n groups from fatty acid side
chains in lipids, in particular, HDL) and δ3.22 (due to choline-N(CH3)3+).
A lipidomic approach was used by Sun et al. to study the plasma
metabolome of patients with unstable angina and atherosclerosis con-
trols and suggested that 16 potential biomarkers could aid in diagnosis
of unstable angina. Phytosphingosine and phosphatidylcholine were
elevated, and phosphatidylglycerol was reduced relative to the athero-
sclerosis control[36].
Similarly, Stübiger et al. [37] used targeted lipidomics to study the
plasma in young patients with familial hyperlipidemia that are at higher
risk to develop ACD. Signiﬁcant alteration of sphingomyelin
(SM)/phophatidylcholine (PC) and phosphatidylcholine (PC)/lyso-
phosphatidylcholine (LPC) and positive correlation of SM with LDL-C
and LPC with VLDL-C were found in the familiar hyperlipidaemic group
in contrast to normolipidaemics. Further, a positive correlation of oxidised
PC with IMT and HDL-C but negative correlation with oxidised LDL was
observed.
Using quantitative MS-based metabolic proﬁling in 117 Caucasians
with strong family history of premature ACD, Shah et al. [38] showed
signiﬁcantly increased ketone bodies (B-hydroxybutarate), several
amino acids, e.g., glutamate and glutamine, free fatty acids (arachidonic
acid) and most notably acylcarnitine. Acylcarnitine facilitates the entry
of long-chain fatty acids into the mitochondrion via the carnitine shut-
tle, which is critical for its use by the myocardium for ß-oxidation.
Where there are fatty acid oxidation defects, acylcarnitine species
accumulate and are released into the circulation. In a follow-up study,
the authors distinguished the metabolic proﬁle of 314 ACD patients
from controls based on differences in branched-chain amino acids
and acylcarnitines between patients and controls. Interestingly, the
dicarboxylacylcarnitine was associated with the incidence of CV
events [39].
Comparative use of techniques has also been tested by Teul et al. [40],
who investigated the plasma of 9 patients with stable carotid atheroscle-
rosis and 10 healthy individuals. They showed that a combination of both
gas chromatography–mass spectrometry (GC-MS) and NMR resulted in a
broader collection of deranged metabolites than using either method
alone. They also reported alteration of many metabolomics path-
ways, such as amino acid metabolism, decrease in metabolites of
Krebs cycle and pyruvate and an elevation of ketone bodies and
2,3,4 trihydroxybutarate (THD). Most of the changes can be associat-
ed with alterations of the metabolism characteristics of insulin resis-
tance that can be strongly related to the metabolic syndrome.
To investigate the effect of age on the progression of ACD, Rizza et al.
[41] using MS were able to proﬁle 49 metabolites in elderly with a high
rate of previous ACD. They suggested that the metabolic proﬁle in
elderly was associated with mitochondrial dysfunction and damage
and those speciﬁc metabolites could aid in the prediction of major CV
events.
Zheng et al. [42] investigated the variability on human serummeta-
bolic proﬁle in communities at risk of atherosclerosis. They calculated
intraclass correlation coefﬁcients (ICC) for 178 metabolites detectedby untargeted method in 60 patients. They observed that pathways of
lipid and amino acidmetabolismhad a relatively high ICCs and thatme-
tabolites in carbohydrate pathway showed relatively low ICCs.
2.3. Lipidomics and atherosclerosis
The predictive value of metabolomics has also been studied. Studies
of lipid proﬁles indicate that individualswith smaller particle LDL have a
greater CV risk compared to those with larger particle LDL. McMahan
et al. [4] studied the LDL subclasses using H-NMR spectroscopy with
carotid intimal-medial thickness (IMT) detected by ultrasound and
found that both forms of LDL were signiﬁcantly associated with IMT, but
the large and small LDL particles were inversely correlated. Furthermore,
Shah et al. [43], using MS in over 2000 patients undergoing cardiac cath-
eterisation, identiﬁed ﬁvemetabolites associatedwith a highermortal-
ity, namely, the medium chain acylcarnitines, short- and long-chain
dicarboxylacylcarnities, branched-chain amino acids and fatty acids.
In 4309 healthy sera of individuals,Wurtz et al. observed using NMR
that increasing concentrations of VLDL, intermediate-density lipopro-
tein (IDL) and LDL subclasses and low concentrations of HDLwere asso-
ciatedwith phenotypes thatwere at the greatest risk for atherosclerosis,
ﬁndings that mirror biochemistry [44]. Likewise, the urine proﬁle of
4630 patients from four populations groups (Japan, China, UK, USA)
showed that alanine correlated positively while hippurate correlated
inversely with blood pressure [45]. The same technique has been shown
to differentiate between high- versus low-risk individuals based on con-
ventional atherosclerosis risk factors (cholesterol, triglycerides, LDL and
HDL). Low-risk individuals had high 3-hydroxybutarate and low levels
of threonine, whereas higher risk individuals were associated with low
level of a ketoglutare anddimethylglycine [46]. TheHDL inhumanplasma
has recently been shown to play a central role in atheroprotection.
Lipidomic approach revealed that the abundance of PC, LPC PS and PA
was elevated in small, dense in contrast to large, light HDL; the inverse
occurred for sphingomyelin and ceramide. Interestingly, several compo-
nents of HDLwere strongly correlatedwith antioxidative, antithrombotic,
anti-inﬂammatory and antiapoptotic activity [47]. Intraplaque lipids have
also been analysed by Stegemann et al. [48], who showed a higher
concentration of polyunsaturated cholesteryl esters with long-chain
fatty acids and certain sphingomyelin.
The effect of inducible myocardial ischaemia was also tested in 36
patients using MS, and 23 metabolites were signiﬁcantly altered in the
ischemic group but not in controls, while six metabolites were related
to the Krebs cycle, including citric acid with a high degree of accuracy.
Oxaloacetate and citruline were signiﬁcantly reduced in the ischemic
group and correlated with the severity of ischemia [49].
2.4. Proteomics and atherosclerosis
Proteomics have also been studied in individuals and patients with
atherosclerosis. In 359 urine samples from individuals with severe
ACD using capillary electrophoresis coupled to ESI-TOF-MS, Zimmerli
et al. [50] identiﬁed 15 metabolites, which discriminated between
patients and healthy controls with a 98% sensitivity and 83% speciﬁcity
as well as with the level of exercise after coronary intervention. Subse-
quently, the same authors reported 238 discriminatory biomarkers in
another sample of ACD patients with a sensitivity of 79% and speciﬁcity
of 88%. Among these markers were fragments ofα1-antitrypsin, collagen
type 1 and 3, granin-like neuroendocrine peptide precursors, membrane-
associated progesterone receptor component 11, sodium potassium
ATPase gamma chain and ﬁbrinogen alpha chain [51].
Early proteomicmarkers of ACDhave also been studied byDelles et al.
using (CE-MS) in ApoE-deﬁcient mice fed a high-fat diet compared to a
low fat diet. Polypeptide fragments of alpha1-antitrypsin, epidermal-like
growth factor and collagen allowed identiﬁcation of atherosclerosis with
a sensitivity of 90% and 100% speciﬁcity. Furthermore, using immunohis-
tochemistry, α1-antitrypsin, EGF and collagen type I were shown to be
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artery, metabolomics studies have also been carried out on the aorta.
Mayr et al. [53] using NMR spectroscopy analysed progressive aortic
atherosclerotic lesions of Apo E(−/−) mice and reported ﬁbrinogen,
transferrin, haemopexin and immunoglobulins. ApoA1 (a component of
HDL) and reduced 1-Cys-peroxiredoxin, an antioxidant, were signiﬁcant-
ly decreased, while the antioxidant 1-Cys-peroxiredoxin was elevated.
In addition tourine and tissue samples, proteomic approaches showed
great promise in plasma analysis. Donahue et al. [54] in an attempt to
determine the plasma proteome of 53 patients with angiographically
diagnosed ACD and controls, which were analysed by LC-MS. As many
as 95 proteins (involved with immune defense, inﬂammation, growth
and coagulation) were discerned in patients vs controls. Even in patients
with acute coronary syndrome, Dardé et al. [55] identiﬁed similar altered
proteins at day 0, 4, 60 and 180 using 2D gel electrophoresis.
2.5. Association of metabolites with atherosclerosis risk factors
Spijkers et al. studied the plasma metabolome and isolated arterial
tissue from spontaneous hypertensive rats (SPR) and Wistar–Kyoto
(WKY) normotensive rats and found altered sphingolipid metabolism
in the former group. They also observed endothelium-dependent
contraction in the arteries of SHR but not in WKY upon administration
of a sphingosine kinase inhibitor (SKI) or sphingomylinase. These
contractions were mediated by ceramide, which was elevated in the
plasma and correlated with severity of hypertension[56]. Ceramide is
known to cause apoptosis [57] and vascular dysfunction [58].
In humans, plasma lipidomicswere studied in 19 hypertensive and 51
normotensive males. Graessler et al. [59] observed a signiﬁcant reduction
of ether phosphatidylcholines and ether phosphatidylethanolamies and
suggested that these ether lipids could contribute to development of
hypertension. More speciﬁcally those reduced ether lipids constituted
arachidonic acid. In addition, among the obese subjects, there was a
signiﬁcantly increased level of saturated triacylglycerides (TAG) and
diacylglycerol (DAG).
Furthermore, testing of Mexican Americans at risk of dyslipidaemia
and insulin resistance demonstrated that higher systolic blood pressure
was signiﬁcantly associated with DAG and that the diastolic blood
pressure was associated with elevated levels of monohexosylcermide,
phosphatidylcholine and DAG [60]. Considering that DAG acts on
TRPC6 channel mediating vasoconstriction [61], it was proposed as a
potential marker for hypertension. Also, a comparative study between
African Americans and Caucasians showed signiﬁcant reduction in
palmitic, oleic, pamitoleic, aracidonic and linoleic free fatty acids in the
latter compared to the former [62].
In a recent study, Zheng et al. [63] investigated the serumof patients
with incident hypertension. Upon using gas chromatography–mass
spectrometry and liquid chromatography, they found a signiﬁcant
association between six steroids and the risk of incident hypertension
(highest versus lowest quintile hazard ratio, 1.72; 95% conﬁdence
interval, 1.05-2.82; P for trend, 0.03), in both men and women.
3. Conclusion
The current state of understanding atherosclerosis pathophysiology
and its relationship to risk factors is not entirely comprehensive neither
satisfactory, particularly in various groups of patients who do not ﬁt
within the one big box. Metabolomics investigations seem to have
great potential in identifying small groups of disturbed metabolites,
which if put together should draw various metabolic routs that lead to
the common track pathophysiology. Nevertheless, this association
does not necessarily imply that these disturbedmetabolites have caused
the atherosclerosis; other potential explanations include the atheroscle-
rosis causing the disturbed metabolites or that the metabolites are
simplymarkers for the disease. The current evidence in usingmetabolo-
mics in atherosclerotic cardiovascular disease is limited and more welldesigned studies remain to be established which might signiﬁcantly
improve our comprehension of the disease process and particularly
before investigation of pharmaceutical agents.Conﬂicts of interest
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